Cargando…
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
We performed single-cell RNA-sequencing and T cell receptor clonotype tracking of breast and ovarian cancer patients treated with the CDK4/6 inhibitor ribociclib and PD-1 blockade. We highlight evidence of two orthogonal treatment-associated phenomena: expansion of T cell effector populations and pr...
Autores principales: | Ali, Lestat R., Garrido-Castro, Ana C., Lenehan, Patrick J., Bollenrucher, Naima, Stump, Courtney T., Dougan, Michael, Goel, Shom, Shapiro, Geoffrey I., Tolaney, Sara M., Dougan, Stephanie K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884581/ https://www.ncbi.nlm.nih.gov/pubmed/36688919 http://dx.doi.org/10.1084/jem.20220729 |
Ejemplares similares
-
Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023) -
IFNγ is a central node of cancer immune equilibrium
por: Walsh, Michael J., et al.
Publicado: (2023) -
Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression
por: Walsh, Michael J, et al.
Publicado: (2023) -
CDK4/6 inhibition in breast cancer: current practice and future
directions
por: Pernas, Sonia, et al.
Publicado: (2018) -
Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
por: Stump, Courtney T., et al.
Publicado: (2021)